EGFR Advisors' Network (EAN) for metastatic colorectal cancer (mCRC)
Vienna, April 8–9, 2011

Chairs: W Scheithauer
R Adam

Treatment aim: Symptom-free survival

Werner Scheithauer

Vienna University Medical School
Vienna, Austria

Patient groups in non-resectable mCRC

Group 1

Patients with metastases that might become resectable

Group 2

Patients with non-resectable metastases, high tumor burden, or tumor-related symptoms

Rapid tumor shrinkage & symptom relief

Group 3

Patients with non-resectable metastases, asymptomatic and less aggressive disease

Schmoll H-J, Sargent D. Lancet 2007;370:105–107

Inducing tumor regression is essential



Expert review from ICACT 2009: Optimizing 1st-line treatment for mCRC

- For patients who present with symptomatic and aggressive disease, rapid tumor shrinkage is essential and likely to relieve symptoms
- For these patients, the recommended treatment is similar to that used in the neoadjuvant setting
- The best chemotherapeutic treatment option is a combination regimen, eg, FOLFOX or FOLFIRI
- Addition of biologic agents may increase response rate and prolong PFS, OS, and symptom-free survival, with the aim of improving quality of life

Adam R, et al. Ann Oncol 2010;21:1579–1584

Response rates with ERBITUX



*Investigator-assessed response at 12 weeks

[1]Van Cutsem E, et al. ASCO GI 2010, Abstract No. 281; [2]Bokemeyer C, et al. ASCO GI 2010, Abstract No. 428; [3]Maughan T, et al. ECCO-ESMO 2009, Abstract No. 6LBA; [4]Folprecht G, et al. Lancet Oncol 2010; [5]Garufi C, et al. Br J Cancer 2010;103:1542–1547; [6]Samalin E, et al. WCGIC 2009, Abstract No. 462.

Early tumor shrinkage at first CT scan:

Relationship to outcomes?

CRYSTAL: 8-week tumor regression according to treatment in patients with KRAS wt tumors

A time-dependent receiver operating curve analysis identified the best cut-off to use as a predictive variable for outcome was a ≥20% tumor shrinkage at week 8 (the first CT scan)



Piessevaux H, et al. ESMO 2010, Abstract No. 596P

CRYSTAL: Early tumor shrinkage at week 8 by KRAS mutation status and treatment



Piessevaux H, et al. ESMO 2010, Abstract No. 596P

CRYSTAL: Early tumor shrinkage and PFS and OS in patients with KRAS wt tumors treated with FOLFIRI and ERBITUX

PFS



OS



* Radiological evaluation reported by the investigator and reviewed by an IRC

Piessevaux H, et al. ESMO 2010, Abstract No. 596P

OPUS: Early tumor shrinkage at week 8 according to treatment in KRAS wt patients



Piessevaux H, et al. ASCO GI 2011, Abstract No. 398

OPUS: Early tumor shrinkage at week 8 by KRAS mutation status and treatment



Piessevaux H, et al. ASCO GI 2011, Abstract No. 398

OPUS: Early tumor shrinkage and PFS and OS in patients with KRAS wt tumors treated with FOLFOX4 and ERBITUX

PFS



OS



* Radiological evaluation reported by the investigator and reviewed by an IRC

Piessevaux H, et al. ASCO GI 2011, Abstract No. 398

Is there an association between tumor response and symptom relief?

Data from the CRYSTAL study

Tumor response in symptomatic patients

- **In patients with symptomatic disease at baseline, a higher proportion developed a response in the FOLFIRI + ERBITUX group than the FOLFIRI-alone group (52% vs 30%)**



Griebsch et al. 2011 ASCO GI, Abstract No. 476

Tumor response in asymptomatic patients

- **In patients with asymptomatic disease at baseline, a higher proportion developed a response in the FOLFIRI + ERBITUX group than the FOLFIRI-alone group (65% vs 52%)**



Griebsch et al. 2011 ASCO GI, Abstract No. 476

Reporting of symptoms by tumor response and treatment

- In patients with **symptomatic disease at baseline**, at each assessment timepoint, fewer patients who were responders reported symptoms than those who were non-responders



- The largest trend was seen for patients treated with FOLFIRI + ERBITUX at week 8

Griebsch et al. 2011 ASCO GI, Abstract No. 476

Association between tumor response and QoL

- For those patients with symptoms, tumor response was associated with symptom relief
- Responders who were asymptomatic at baseline were more likely to remain asymptomatic post-baseline than non-responders
- The association between symptom relief and tumor response is independent of treatment
  - However, the magnitude of the effect appears to be greater in patients treated with FOLFIRI + ERBITUX

Griebsch et al. 2011 ASCO GI, Abstract No. 476

Conclusions

- In patients with non-resectable, symptomatic mCRC and KRAS wt tumors ± high tumor burden the best available treatment is combination chemotherapy with ERBITUX
- A particular therapeutic benefit is noted in patients with an early tumor shrinkage ≥20%
- There is a clear correlation between tumor response and symptom relief, which appears to be greatest in patients treated with ERBITUX combination chemotherapy

EGFR Advisors' Network (EAN) for metastatic colorectal cancer (mCRC)
Vienna, April 8–9, 2011

Chairs: W Scheithauer
R Adam